NUVB Nuvation Bio Inc
Price (delayed)
$1.79
Market cap
$606.24M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.11
Enterprise value
$579.43M
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and
Highlights
The company's gross margin has surged by 131% QoQ
NUVB's EPS is up by 3.2% QoQ
Nuvation Bio's debt has surged by 122% YoY but it has decreased by 20% QoQ
The company's quick ratio has shrunk by 80% YoY and by 4.8% QoQ
NUVB's equity is down by 23% year-on-year and by 8% since the previous quarter
Key stats
What are the main financial stats of NUVB
Market
Valuations
Earnings
Shares outstanding
338.68M
Market cap
$606.24M
Enterprise value
$579.43M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.3
Price to sales (P/S)
61.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
73.6
Revenue
$7.87M
Gross profit
$795,000
Operating income
-$592.63M
Net income
-$567.94M
EBIT
-$567.6M
EBITDA
-$567.09M
Free cash flow
-$130.58M
Per share
Balance sheet
Liquidity
EPS
-$2.11
EPS diluted
-$2.11
Free cash flow per share
-$0.49
Book value per share
$1.38
Revenue per share
$0.03
TBVPS
$1.99
Total assets
$540.63M
Total liabilities
$76.84M
Debt
$8.92M
Equity
$463.79M
Working capital
$468.01M
Debt to equity
0.02
Current ratio
9.04
Quick ratio
8.85
Net debt/EBITDA
0.05
Margins
Efficiency
Dividend
EBITDA margin
-7,202.9%
Gross margin
10.1%
Net margin
-7,213.8%
Operating margin
-7,527.3%
Return on assets
-97.9%
Return on equity
-125%
Return on invested capital
-111.9%
Return on capital employed
-117.7%
Return on sales
-7,209.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NUVB stock price
How has the Nuvation Bio stock price performed over time
Intraday
2.29%
1 week
-4.79%
1 month
-9.14%
1 year
-48.12%
YTD
-32.71%
QTD
1.7%
Financial performance
How have Nuvation Bio's revenue and profit performed over time
Revenue
$7.87M
Gross profit
$795,000
Operating income
-$592.63M
Net income
-$567.94M
Gross margin
10.1%
Net margin
-7,213.8%
The company's gross margin has surged by 131% QoQ
Nuvation Bio's net margin has surged by 71% QoQ
The operating margin has soared by 71% QoQ
The net income has declined by 7% since the previous quarter
Growth
What is Nuvation Bio's growth rate over time
Valuation
What is Nuvation Bio stock price valuation
P/E
N/A
P/B
1.3
P/S
61.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
73.6
NUVB's EPS is up by 3.2% QoQ
The stock's price to book (P/B) is 66% less than its 5-year quarterly average of 3.7 and 29% less than its last 4 quarters average of 1.8
NUVB's equity is down by 23% year-on-year and by 8% since the previous quarter
Efficiency
How efficient is Nuvation Bio business performance
NUVB's ROS has soared by 71% QoQ
NUVB's ROE is down by 15% from the previous quarter
The return on invested capital has declined by 13% since the previous quarter
NUVB's return on assets is down by 10% since the previous quarter
Dividends
What is NUVB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NUVB.
Financial health
How did Nuvation Bio financials performed over time
The company's quick ratio has shrunk by 80% YoY and by 4.8% QoQ
The current ratio has shrunk by 80% YoY and by 6% QoQ
Nuvation Bio's debt is 98% lower than its equity
Nuvation Bio's debt has surged by 122% YoY but it has decreased by 20% QoQ
The debt to equity has soared by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.